Rabin presents at rodman renshaw conf on sept 13th at 10:25am in NEW York City and sept 14th at the USA stem cell conf in boston at 2:35 pm---info on Boston conf below
Gary Rabin,
Chairman and CEO
Advanced Cell Technology
Gary Rabin has a 23-year career in finance and operations that primarily encompasses investing in, managing and capital-raising for small-cap and emerging growth companies. From 2007 to 2010, he was the Managing Partner of GR Advisors, LLC, investment manager for two long/short hedge funds focused on the media and communications industry. Until June 2007, he was a Portfolio Manager at MACInvestment Management, LLC (“MAC”), which he joined in November 2005. MAC was a long/short fundamental equity hedge fund concentrating on growth-oriented stocks including technology, communications and healthcare. Previously, he was a Managing Director and Portfolio Manager at Marketus Associates, a long/short hedge fund where he focused on communications, healthcare services, energy and special situations. Prior to that, he was Managing Director and Co-Head of the Media and Telecom Investment Banking Group at CIBC World Markets (“CIBC”), where he was responsible for all corporate finance and M&A, financial restructurings, and principal investing activities (both debt and equity) within the sector. Before joining CIBC, Mr. Rabin served in an operating capacity at a broadband services company when he was Chief Strategy Officer of CAIS Internet, Inc. (“CAIS”). At CAIS, he was responsible for raising over $500 million of financing commitments in both the public equity markets and from his relationships at Kohlberg, Kravis Roberts & Co., Qwest Communications, Cisco, Nortel, 3Com and Microsoft. Mr. Rabin has also started and served as Managing Director and Head of the Global Telecom Investment Banking Group at ING Barings Furman Selz, and was a founder of the telecom group at UBS Securities. He began his career in finance in 1987, and concentrated on energy, utilities, and metals until 1993. Throughout his career, Mr. Rabin has been responsible for building and developing businesses. Mr. Rabin earned an AB in Economics from the University of Michigan.
Appearing:
Conference Day 2: Wednesday 14th September - Afternoon stream A
2.35pm
Using ESC-derived RPE cells for Dry AMD and Stargardt’s disease
Clinical update on ACT’s studies of sub-retinal transplantation for Dry AMD and Stargardt’s disease
What were the major challenges encountered to date? What can other organizations learn from ACT’s experiences?
Applying lessons learned to future development: is this the light at the end of the tunnel for stem cell therapies’ acceptance?
Gary Rabin,
Chairman and CEO,
Advanced Cell Technology
